You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

EVENTS

ISTH, Kedrion supports symposium on the importance of inhibitor eradication

The central theme of the round table will be the optimization of the treatment of patients with Hemophilia A

read more 

EVENTS

Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020

The company reaffirms its commitment to the patient community during the COVID-19 epidemic

read more 

CORPORATE

Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel

The two companies are now working to expand the Clinical Development Program to the US

read more 
  1. EVENTS - 29-04-2019

    16th International Hemophilia Congress in Turkey

    A scientific symposium on the prevention and eradication of inhibitors in patients affected by Hemophilia A

    read more 
  2. CORPORATE - 30-01-2019

    Kedrion Biopharma Announces Completion of Enrollment for CARES10

    A Phase 3, Multi-Center Study to Assess a 10% Ig in Adults with Primary Immunodeficiency Disease

    read more 
  3. CORPORATE - 05-11-2018

    First Annual International Symposium for the Global Eradication of Rh Disease ends a year of celebrations

    The event, supported by Kedrion among others, was held on November 1st at Columbia University in NY

    read more 
  4. EVENTS - 26-10-2018

    Kedrion renews its commitment to PID patients at ESID 2018

    18th edition of the Biennial Meeting of the European Society for Immunodeficiencies helds in Lisbon (Oct. 24 to 27)

    read more 

Pages

For more information please contact: pressoffice@kedrion.com